BiVictriX Therapeutics plc (AIM: BVX)

Market Cap	8.25M
Revenue (ttm)	n/a
Net Income (ttm)	-2.67M
Shares Out	82.53M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,448,022
Open	8.68
Previous Close	8.50
Day's Range	8.63 - 10.00
52-Week Range	0.11 - 14.39
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 17, 2024

About BiVictriX Therapeutics

BiVictriX Therapeutics plc, a biotechnology company, engages in the research and experimental development of pharmaceutical products in the United Kingdom. The company develops Bi-Cygni, a proprietary platform that combines the discovery of novel, cancer-selective twin-antigen pairs or fingerprints with bispecific antibody engineering insights to create anti-cancer therapeutics. Its lead program is BVX001, a first-in-class Bi Cygni antibody drug conjugates to treat acute myeloid leukemia. The company also develops BVX002 for treating ovarian an...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 17
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: BVX